Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 13/20 | 0.67 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20029002 | 0.96 | USP30 (0.65) | USP30GPR119JAK2JAK1 | |
| SCHEMBL20029001 | 0.96 | USP30 (0.65) | USP30GPR119JAK2JAK1 | |
| SCHEMBL20028902 | 0.94 | USP30 (0.67) | USP30GPR119JAK2JAK1 | |
| SCHEMBL20028904 | 0.94 | USP30 (0.67) | USP30GPR119JAK2JAK1 | |
| SCHEMBL21145394 | 0.88 | USP30 (0.75) | USP30 | |
| SCHEMBL20028869 | 0.84 | USP30 (0.48) | USP30GPR119 | |
| SCHEMBL21145371 | 0.83 | USP30 (0.72) | USP30 | |
| SCHEMBL21145373 | 0.83 | USP30 (0.72) | USP30 | |
| SCHEMBL28779046 | 0.82 | USP30 (0.67) | USP30GPR119JAK2JAK1 | |
| SCHEMBL20028854 | 0.82 | USP30 (0.67) | USP30GPR119JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519397-B1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2019-07-18 | — | — | US | disclosed |
| WO-2018060691-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218215-A1 | CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | USP30 1/4885GPR119 3726/4885JAK2 2956/4885 |
| US-10927110-B2 | Cyano-subtituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | USP30 1/4885GPR119 3726/4885JAK2 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.